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Introduction
Until now, treatment of sepsis has been characterized by 
two revolutionary steps that significantly improved sur-
vival: the introduction of antibiotics and the development 
of intensive care units (ICUs). Whereas antibiotics target 
the pathogen, all other treatments focus on support of 
the host. As sepsis is defined as a life-threatening organ 
dysfunction caused by a dysregulated host response to 
an infection [1], a third revolution—immunotherapy tar-
geting the patient’s immune reaction—might be at the 
break of dawn to further improve the outcome of sepsis 
patients.
Previously, immunotherapy for sepsis completely 
focused on attenuation of the immune response, e.g., by 
employing pharmacological inhibition of lipopolysaccha-
ride, Toll-like receptor 4 signaling, or pro-inflammatory 
cytokines [2]. Without exceptions, these attempts have 
been unsuccessful, plausibly related to ignorance pertain-
ing to the heterogeneity of the immune response in sepsis 
and failure to stratify patients on the basis of their cur-
rent immune status. Patient selection was merely based 
on severity of disease, resulting in prognostic enrichment: 
patients expected to have a high event rate (e.g., 28-day 
mortality) were selected. However, this does not take into 
account the likelihood of success of the immunomodu-
latory treatment under investigation, as this depends 
on the specifics of the host response of that patient [3]. 
Biological plausibility leads to predictive enrichment and 
increases the chances to demonstrate clinical efficacy.
Activation of both pro- and anti-inflammatory immune 
responses occurs promptly after sepsis onset. While 
overzealous inflammation may indeed be responsible 
for “collateral” organ damage, we now know that sepsis-
induced immunoparalysis also contributes to mortality. 
Emerging techniques allow us to chart the hosts’ genome, 
epigenome, transcriptome, and metabolome. This multi-
layered omics-based immunoprofiling will provide 
detailed information to facilitate novel precision immu-
notherapies in sepsis. For example, patients with sepsis 
admitted to the ICU can be subdivided in so-called endo-
types with pathophysiologic and prognostic implications 
based on their blood leukocyte gene expression profiles 
[4, 5]. The signaling pathways that emerged are relevant 
to the innate and adaptive immune system. Because a 
patient with a certain endotype displays higher expres-
sion of genes corresponding to a specific signaling path-
way, it is biologically plausible that they are more likely 
to respond to a treatment aimed at this pathway. Analy-
ses limited to neutrophil CD88, HLA-DR and percentage 
of regulatory T cells as markers of immune dysfunction 
illustrated a progressive increase in risk of secondary 
infections from 14% of ICU patients with no immune 
dysfunction to 59% with dysregulation of all three mark-
ers [6]. Of interest, a combination of prognostic and pre-
dictive strategies based on serum protein and messenger 
RNA biomarkers could identify a subgroup of children 
with septic shock that may be more likely to benefit from 
corticosteroids [7], illustrating the validity of predictive 
enrichment.
Immunostimulatory compounds
Several immuno-adjuvant agents are under investigation, 
including granulocyte–macrophage colony-stimulating 
factor (GM-CSF), interferon-gamma (IFN-γ), anti-pro-
grammed death-ligand 1 (anti-PD-L1), and interleukin-7 
(IL-7). GM-CSF and IFN-y are potent enhancers of mye-
loid cell function. A biomarker-guided randomized con-
trolled trial (mHLA-DR < 8000 monoclonal antibodies/
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cell) showed that GM-CSF was effective in restoring 
monocytic immunocompetence and appeared to be 
associated with beneficial clinical outcomes [8]. IFN-γ 
showed promising results in several small case series 
[9], and a randomized controlled trial is currently being 
conducted (NCT03332225). Blockade of PD-1 pathway 
represents another promising strategy. These antibodies 
are known as checkpoint inhibitors, because they stop 
potentially autoreactive T  cells at the initial or priming 
stage of naive T cell activation. A phase 1b trial with anti-
PD-L1 (NCT02576457) in 24 sepsis patients yielded no 
unexpected safety findings. Immune restoration at higher 
dosages was evidenced by a trend toward increased 
mHLA-DR expression over time (personal communica-
tion, Professor R. Hotchkiss). Unfortunately, a large mul-
ticenter trial was recently aborted by the sponsor because 
of other priorities. IL-7 is an anti-apoptotic cytokine that 
is essential for lymphocyte proliferation and survival. 
IL-7 increases the number and function of CD4 helper 
T cells, and was found to exert a broad and long-lasting 
effect on immunity, while no safety issues emerged in a 
phase 2 trial in 27 patients with septic shock and lym-
phopenia [10]. To what extent the described effects trans-
late into clinical benefit for sepsis patients needs to be 
determined.
Other patient groups in the ICU
The development of immunoparalysis does not exclu-
sively occur in sepsis patients. It has become clear 
that not only pathogen-associated molecular patterns 
(PAMPs) but also danger-associated molecular pat-
terns (DAMPs) induce immunosuppressive effects. In 
multiple trauma patients, increased levels of DAMPs, 
related to cytokine responses and decreased HLA-DR 
expression, were shown to be associated with the devel-
opment of secondary infections [11]. Similarly, release 
of DAMPs following cardiac arrest is associated with 
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Fig. 1 Displaying the current therapy and the conventional and proposed method to approach new investigational immunomodulatory treat-
ment. The conventional methodology to investigate new compounds is to apply inclusion and exclusion criteria aimed to select a patient group 
with focus on mortality, called prognostic enrichment. Biological plausibility for the new compound to exert therapeutic efficacy is not taken into 
account. Trials that used this methodology did not show therapeutic efficacy of the compounds tested, e.g., IL1-receptor blocker anakinra [14]. 
If immunophenotyping is used to select patients, e.g., with an overactive but ineffective immune response, for example macrophage activation 
syndrome, IL-1 pathway inhibition might exert therapeutic efficacy [15]. In another subgroup of patients with a suppressed immune system, immu-
nostimulatory therapies appear more likely to improve the outcome of the patient. Secondary to this so-called predictive enrichment, prognostic 
enrichment could still be applied if it is desired to select patients, e.g., with a high risk of dying
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the development of immunoparalysis [12], which may 
explain the increased susceptibility of these patients 
toward infections. The combined observations that infec-
tions in these patient groups are related to immunopa-
ralysis and importantly contribute to long-term mortality 
suggest that immunostimulatory therapy might represent 
a treatment possibility for these patients as well (Fig. 1).
In conclusion, it is clear that a patient-tailored 
approach in sepsis treatment is required and that com-
plementary knowledge of host–pathogen interactions 
and cutting-edge omics-based technologies represent 
promising tools to do so. Immunostimulatory therapies 
may represent a viable adjuvant strategy for the treat-
ment of immunoparalyzed patients, which has the poten-
tial to represent a qualitative leap for the prognosis of 
sepsis, as well as other immunoparalyzed patient groups. 
Importantly, new studies aiming to reverse immunopa-
ralysis should not employ a “one size fits all” strategy, as 
a recent observational study shows that secondary infec-
tions are responsible for only 10% of overall sepsis mor-
tality in the ICU [13], raising doubt about the potential 
impact of immune stimulation in unselected sepsis popu-
lations. Clearly, as both hyperinflammation and immu-
noparalysis are of importance in sepsis, it is appreciated 
that they are present in individual sepsis patients to a 
different and time-dependent extent. Clinical benefit of 
immunomodulatory therapies needs to be established, 
arguably using reduction in secondary infections and/or 
improved long-term morbidity as additional endpoints 
besides mortality. In view of the lack of positive results 
following inhibition of inflammation in unselected sepsis 
patients, the only way to break this deadlock is by apply-
ing a precision medicine approach, which may well spark 
a third revolution.
Author details
1 Department of Intensive Care Medicine, Radboud University Medical 
Center, Nijmegen, The Netherlands. 2 Radboud Center for Infectious Diseases, 
Radboud University Medical Center, Nijmegen, The Netherlands. 3 Division 
of Infectious Diseases and Center of Experimental and Molecular Medicine, 
Amsterdam University Medical Centers, Location Academic Medical Center, 
University of Amsterdam, Amsterdam, The Netherlands. 
Compliance with ethical standards
Conflicts of interest
TvdP has no conflicts of interest with relevance for this manuscript. PP has no 
conflicts of interest with relevance for this manuscript.
Received: 10 October 2018   Accepted: 10 November 2018
Published online: 19 November 2018
References
 1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, 
Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM et al (2016) 
The third international consensus definitions for sepsis and septic shock 
(sepsis-3). JAMA 315(8):801–810
 2. van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG (2017) The 
immunopathology of sepsis and potential therapeutic targets. Nat Rev 
Immunol 17(7):407–420
 3. Peters van Ton AM, Kox M, Abdo WF, Pickkers P (2018) Precision immuno-
therapy for sepsis. Front Immunol 9:1926
 4. Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE, 
Burnham KL, Nurnberg P, Schultz MJ, Horn J, Cremer OL et al (2017) Clas-
sification of patients with sepsis according to blood genomic endotype: 
a prospective cohort study. Lancet Respir Med 5(10):816–826
 5. Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills 
TC, Rautanen A, Gordon AC, Garrard C, Hill AV et al (2016) Genomic 
landscape of the individual host response and outcomes in sepsis: a 
prospective cohort study. Lancet Respir Med 4(4):259–271
 6. Conway Morris A, Datta D, Shankar-Hari M, Stephen J, Weir CJ, Rennie 
J, Antonelli J, Bateman A, Warner N, Judge K et al (2018) Cell-surface 
signatures of immune dysfunction risk-stratify critically ill patients: INFECT 
study. Intensive Care Med 44(5):627–635
 7. Wong HR, Atkinson SJ, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, 
Bigham MT, Weiss SL, Fitzgerald JC, Checchia PA et al (2016) Com-
bining prognostic and predictive enrichment strategies to identify 
children with septic shock responsive to corticosteroids. Crit Care Med 
44(10):e1000–e1003
 8. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, 
Weber-Carstens S, Hasper D, Keh D, Zuckermann H et al (2009) Granulo-
cyte-macrophage colony-stimulating factor to reverse sepsis-associated 
immunosuppression: a double-blind, randomized, placebo-controlled 
multicenter trial. Am J Respir Crit Care Med 180(7):640–648
 9. Delsing CE, Gresnigt MS, Leentjens J, Preijers F, Frager FA, Kox M, Mon-
neret G, Venet F, Bleeker-Rovers CP, van de Veerdonk FL et al (2014) 
Interferon-gamma as adjunctive immunotherapy for invasive fungal 
infections: a case series. BMC Infect Dis 14:166
 10. Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, Mon-
neret G, Rimmele T, Blood T, Morre M et al (2018) Interleukin-7 restores 
lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI 
Insight 3(5). https ://doi.org/10.1172/jci.insig ht.98960 
 11. Timmermans K, Kox M, Vaneker M, van den Berg M, John A, van Laar-
hoven A, van der Hoeven H, Scheffer GJ, Pickkers P (2016) Plasma levels 
of danger-associated molecular patterns are associated with immune 
suppression in trauma patients. Intensive Care Med 42(4):551–561
 12. Venet F, Cour M, Demaret J, Monneret G, Argaud L (2016) Decreased 
monocyte HLA-DR expression in patients after non-shockable out-of-
hospital cardiac arrest. Shock 46(1):33–36
 13. van Vught LA, Klein Klouwenberg PC, Spitoni C et al (2016) Incidence, risk 
factors, and attributable mortality of secondary infections in the intensive 
care unit after admission for sepsis. JAMA 315(14):1469–1479
 14. Opal SM, Fisher CJ, Dhainaut J-FA, Vincent J-L, Brase R, Lowry SF, Sadoff JC, 
Slotman GJ, Levy H, Balk RA et al (1997) Confirmatory interleukin-1 recep-
tor antagonist trial in severe sepsis: a phase III, randomized, doubleblind, 
placebo-controlled, multicenter trial. Crit Care Med 25(7):1115–24
 15. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, 
Cron RQ, Opal SM (2016) Interleukin-1 receptor blockade is associated 
with reduced mortality in sepsis patients with features of macrophage 
activation syndrome: reanalysis of a prior phase III trial. Crit Care Med 
44(2):275–281
